Navigation Links
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
Date:11/3/2008

SAN FRANCISCO (November 3, 2008) New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease's (AASLD) Liver Meeting 2008 in San Francisco.

The current standard of care treatment for HCV infection, pegylated interferon (Peg-IFN) combined with ribavirin (RBV), is effective in 30 to 50 percent of patients infected with chronic genotype 1 HCV infection, the most common type in the United States. The development of new therapies and strategies for treating HCV, particularly the introduction of direct antivirals, may offer patients a new option with shorter treatment duration.

TMC435 Phase IIa Study Results

In interim findings from the first 28 days of treatment for the first cohort of fifty (50) treatment nave HCV+, genotype 1, patients (once daily dose of 25 mg or 75 mg TMC435 versus placebo), both doses showed dose-dependent antiviral activity. TMC435 was administered in combination with PegIFNα-2a/RBV (triple therapy) for 28 days or as monotherapy for seven days and, thereafter, in combination with PegIFNα-2a/RBV (triple therapy) for three weeks. There were neither serious adverse events, nor grade 3 or 4 adverse events, related to TMC435 or any safety-related treatment discontinuations during this 28 day treatment period.

The most common adverse events associated with TMC435 were nausea, diarrhea, and headache. There were no clinically relevant changes in laboratory parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively.

Mean
'/>"/>

Contact: Julian Teixeira
julian.teixeira@zenogroup.com
202-965-7808
Zeno Group
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
2. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
3. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
6. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
7. Retirement Living TV Presents Sex, Drugs and Rock N Roll
8. AviaraDx Presents at 2007 BIOCOM Investor Conference
9. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
10. California Science Center Science Matters Speakers Program Presents The Science and Ethics of Fear
11. Borgata Heart & Soul Foundation Presents Third Annual Women in Wine Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... -- A leading group of oncologists has released updated ... advanced breast cancer. HER2-negative breast tumors include ... HER2 protein, the American Society of Clinical Oncology (ASCO) ... 80 percent of women with advanced breast cancer have ... guideline, our aim is to improve both the length ...
(Date:9/2/2014)... latest research on sleep apnea, tonsillectomies, hearing loss, ... will be presented in Orlando, FL, September 21-24, ... of the American Academy of OtolaryngologyHead and Neck ... ear, nose, throat, head and neck physicians in ... be presented were released today, and are available ...
(Date:9/2/2014)... September 02, 2014 The first ... Pinnacle hip implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon ... the U.S. District Court, Northern District of Texas, ... Johnson & Johnson and its DePuy Orthopaedics unit ... all-metal hip caused recipients to suffer serious and ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... leverage Risk MonitorPro, (R) and Feedback ... patient feedback and adverse events,CAMBRIDGE, MA, Jan. 13 ... quality and safety software, announced today that Woman,s Hospital ... and quality of care initiatives. , Named by Modern ...
... Straight Wire Seminars(TM) Celebrates 3 Decades of Orthodontic ... Straight Wire Seminars , Inc., a leading provider ... 30th anniversary starting this month, January 2009. ... milestone by offering a wide array of courses ...
... to enter Animal Health Rapid Diagnostics Market with a ... 13 Abaxis, Inc. (Nasdaq: ABAX ), ... for both the medical and veterinary markets, announced today ... for the manufacturing of a Canine Heartworm Lateral Flow ...
... Merck Serono and Apitope to Collaborate on Development ... the Treatment of Multiple Sclerosis (MS)GENEVA, Jan. 13 ... Darmstadt, Germany, announced today the signature of a ... (Bristol) Ltd., a wholly owned subsidiary of Apitope ...
... The National Eczema Association (NEA) awarded its Seal ... Theraplex Clear Lotion .The NEA Seal of Acceptance is ... program, which is intended to improve the quality of ... skin. "These products met our criteria for having no ...
... and Web 2.0 as Top Security Concerns and Steps Organizations Need to ... ... Ariz. (PRWEB) January 13, 2009 -- What will be the biggest threats ... 24 months? Cybercrime, data breaches , Web 2.0 and outsourcing were ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:Don't Trust Any Continuing Education Provider Under 30 2Health News:Don't Trust Any Continuing Education Provider Under 30 3Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 2Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 3
(Date:9/2/2014)... -- Reportlinker.com announces that a new market research report is ... Taiwanese Markets for Minimally Invasive Spinal Devices ... market for MIS spinal devices in the ... a fast pace, albeit at different rates in different ... China , where MIS spinal fusion is ...
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
Breaking Medicine Technology:Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6
... announced today that Apligraf®, the only product with FDA ... and venous leg ulcers, will have two new procedure ... Services (CMS) as of January 2011. The new codes ... application of Apligraf in accordance with its FDA labeling ...
... 10, 2010 Filtrona Porous Technologies, a custom ... fiber components designed to absorb, retain, transfer, filter ... expanded range of polyurethane foams and bonded fibers ... Dusseldorf, Germany from 17 to 19 November 2010. ...
Cached Medicine Technology:Apligraf Reimbursement to Benefit from New CMS Codes 2
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: